Is Aurinia Pharmaceuticals Inc. (AUPH) a Buy, Sell, or Hold?
NASDAQ : AUPH
Aurinia Pharmaceuticals Inc.
$14.96 USD
-$0.26 (-1.71%)
- Volume
- 1.69M
- Average Volume
- 1.49M
- Market Capitalization
- $1.92B
- P/E Ratio
- 6.68
- Dividend Yield
- 0.00%
- Price Target
- $13.00
- Year High
- $19.25
- Year Low
- $8.80
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.55
Company Overview
NASDAQ
Kevin C. Tang
Biotechnology
Healthcare
AUPH
128
CA
USD
Liquidity Metrics
0.12
5.55
5.01
0.47
0.00
Sales & Valuation
$283.06M
6.45
3.49
11.62
1.25
Profitability
$2.07
$287.2M
99.97%
44.83%
64.48%
41.19%
P/E Metrics
6.68
0.01
0.01
Analyst Price Target & Rating
$13.00
$16.00
$6.00
4/5
15 Analysts
15.08%
Financial Health Scores
8.10
6/9
$393.69M
$724M
$156.37M
$142.38M
Key Metrics (TTM)
$1.98B
6.65
12.27
5.55
64.48%
18.99%
14.80%
8.46%
$14.74
582 days
Company Executives
| Name | Title |
|---|---|
| Stephen Robertson | Chief Legal Officer, Corporate Secretary & Chief Compliance Officer |
| Stewart Kroll | Chief Development Officer |
| Thomas Wei | Chief Scientific Officer |
| Kevin C. Tang | Chairman & CEO |
| Michael S. Hearne | Chief Financial Officer |
| Ryan Cole | Chief Operating Officer |
| Peter S. Greenleaf | Consultant |
Poll Results
No votes yet today — be the first to share your view!
About Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada. ...
Playing The Biotech Breakout With Insiders
2026-07-23 15:15:20
Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking Alpha Quant Ratings. ABCL's Phase 2 efficacy readout for ABCL635 in Q3 and ACOG's Zunveyl sales ramp are key catalysts. Both have substantial upside per analyst targets.
2026-07-06 09:00:00
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNISÂ
2026-07-06 08:00:00
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS® and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis (ClinicalTrials.gov). Planned enrollment is approximately 150 patients across approximately 50 sites in the US. The Study's primary endpoint is the proportion of patients achieving complete renal response (CRR).
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why
2026-07-02 13:01:14
Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
2026-06-26 06:01:05
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
2026-06-25 09:41:16
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
2026-06-23 08:11:08
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million
2026-06-07 07:57:26
814,606 common shares acquired for a total transaction value of approximately $12.5 million, based on a weighted average price of $15.29 per share. The purchase represents 6.66% of Kevin Tang's total holdings prior to the transaction, with direct ownership unchanged at zero shares post-transaction.
Frequently Asked Questions
-
What is the current Aurinia Pharmaceuticals Inc. (AUPH) stock price?
-
Aurinia Pharmaceuticals Inc.(NASDAQ:AUPH) stock price is $14.96 in the last trading session. During the trading session, AUPH stock reached the peak price of $19.25 while $8.8 was the lowest point it dropped to. The percentage change in AUPH stock occurred in the recent session was --1.71% while the dollar amount for the price change in AUPH stock was -$0.26.
-
AUPH's industry and sector of operation?
-
The NASDAQ listed AUPH is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AUPH?
-
Stephen Robertson | Chief Legal Officer, Corporate Secretary & Chief Compliance Officer
Stewart Kroll | Chief Development Officer
Thomas Wei | Chief Scientific Officer
Kevin C. Tang | Chairman & CEO
Michael S. Hearne | Chief Financial Officer -
How many employees does AUPH have?
-
Number of AUPH employees currently stands at 128. AUPH operates from 4464 Markham Street, Edmonton, AB V8Z 7X8, CA.
-
Link for AUPH official website?
-
Official Website of AUPH is: https://www.auriniapharma.com
-
How do I contact AUPH?
-
AUPH could be contacted at phone #12507084272 and can also be accessed through its website. AUPH operates from 4464 Markham Street, Edmonton, AB V8Z 7X8, CA.
-
How many shares of AUPH are traded daily?
-
The average number of AUPH shares traded daily for last 3 months was 1.49M.
-
What is the market cap of AUPH currently?
-
The market value of AUPH currently stands at $1.92B with its latest stock price at $14.96